SAiGENCI

The South Australian immunoGENomics Cancer Institute (SAiGENCI) is an independent cancer-focused medical research institute located in South Australia, focusing on cancer research and clinical trials, which will include new cutting-edge technologies in immunotherapies and genomics.

The overarching vision for SAiGENCI is to have a fundamentally positive impact on the conduct of cancer research in South Australia, so that fewer patients develop cancer, and the lives of those with cancer is improved.

An alliance between the University of Adelaide and the Central Adelaide Local Health Network (CALHN), the Institute aims to become a hub for scientific discoveries and development of transformative technologies that will translate into improved clinical outcomes.

Principal research area – cancer:

  • Hormone Dependent Cancers
  • Resistance Prevention
  • Cancer Epigenetics
  • Computational Systems Oncology
  • Paediatric and Neuro-oncology
  • Tailored immunotherapy

Director

Professor Christopher Sweeney MBBS